<DOC>
	<DOCNO>NCT02334943</DOCNO>
	<brief_summary>Immune Activation persist HIV-1 infected patient despite efficient antiretroviral treatment . This immune activation responsible immune deficiency well non-AIDS related comorbidities , non-alcoholic Fatty liver disease , metabolic syndrome osteoporosis . The goal observational transversal multicentric study establish etiologic factor persistent immune activation treat HIV-1 infected patient ( persistent de novo infection T CD4+ cell , microbial translocation , active coinfections , immunosenescence , T CD4+ cell lymphopenia , Treg deficiency ) , different form ( activation T CD4+ cell , T CD8+ cell , B cell , NK cell , monocyte , granulocyte , platelet , endothelial cell general inflammation ) potential correlation cause , form immune activation emergent comorbidities ( kidney , bone liver dysfunction , metabolic syndrome ) .</brief_summary>
	<brief_title>Immune Activation HIV-1 Infected Patients Under AntiRetroviral Treatment</brief_title>
	<detailed_description>Immune Activation persist HIV-1 infected patient despite efficient antiretroviral treatment . This immune activation responsible immune deficiency well non-AIDS related comorbidities , non-alcoholic Fatty liver disease , metabolic syndrome osteoporosis . The goal observational transversal multicentric study establish etiologic factor persistent immune activation treat HIV-1 infected patient ( persistent de novo infection T CD4+ cell , microbial translocation , active coinfections , immunosenescence , T CD4+ cell lymphopenia , Treg deficiency ) , different form ( activation T CD4+ cell , T CD8+ cell , B cell , NK cell , monocyte , granulocyte , platelet , endothelial cell general inflammation ) potential correlation cause , form immune activation emergent comorbidities ( kidney , bone liver dysfunction , metabolic syndrome ) . These correlation could highlight physiopathologic mechanism relate specific cause immune activation , activation specific subpopulation immune cell comorbidity . Physiopathologic mechanism could test vitro lead new therapeutic track immune activation secondary HIV-1 natural age process .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Inclusion criterion : Age &gt; = 45 year HIV1 infection Number T CD4+ lymphocytes antiretroviral treatment &lt; 350 cells/mm3 Current number T CD4+ lymphocytes &gt; 200 cell / mm3 6 moth inclusion Efficient well tolerate antiretroviral treatment 24 month HIV1 viral load &lt; 50 copies/ml 24 month inclusion Patient able understand nature , objective method study Patient sign informed consent Affiliation French Social Security System Exclusion criterion : Patient current evidence II IV rank ANRS scale clinical condition Patient current evidence III IV rank ANRS scale biological condition Patient current evidence active coinfection Patient current ( active ) diagnosis acute hepatitis due cause . Patients chronic hepatitis , include chronic hepatitis B and/or C , may enter study long stable liver function test undetectable viral load hepatitis B and/or C Patient cirrhosis Patient present non infectious pathology might give immune modification Patient use immunomodulator therapy chemotherapy Patient currently participate participate study ( within exclusion period define study ) Patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Immune Activation</keyword>
	<keyword>HIV-1 infected subject</keyword>
	<keyword>Undetectable viral load</keyword>
	<keyword>Causes Immune Activation HIV-1 infect patient</keyword>
	<keyword>Forms Immune Activation</keyword>
	<keyword>Emergent non-AIDS related comorbidities</keyword>
</DOC>